BioCureTechnology Inc.CSE: CURE OTCQB: BICTF
Investors PresentationApril 2019
BiocureTechnology
BiocureTechnology
Disclaimer
Forward-Looking Information
Not for Distribution; No Offering
This presentation and the material contained herein are confidential and are not to be disclosed to the public. This presentation is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction. Such an offer can only be made by prospectus or other authorized offering document. This presentation and materials or fact of their distribution or communication shall not form the basis of, or be relied on in connection with any contract, commitment or investment decision whatsoever in relation thereto. No securities commission or similar authority in Canada or any other jurisdiction has in any way passed upon the adequacy or accuracy of the information contained in this presentation.
Forward-Looking Information
Certain disclosure in this presentation, including statements regarding the potential market for BioCure’s products constitute forward-looking statements. In making the forward-looking statements in this release, BioCure has applied certain factors and assumptions that are based on BioCure’scurrent beliefs as well as assumptions made by and information currently available to BioCure, including the assumption that the market for BioCure’sproduct will continue to increase as anticipated. Although BioCure considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this presentation are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, the risk that the market for BioCure product will not increase or continue as anticipated.
Readers are cautioned not to place undue reliance on forward-looking statements. BioCure does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
BiocureTechnology
Executive Summary
• BioCure specializes in the development of BioSimilar
pharmaceutical products
• A social agenda vision; To provide affordable key pharmaceuticals
• A multi-billion dollar market of unmet medical needs
• Unique knowhow and research capabilities
• Advanced stages of trials with planned commercialization in 2020
• Experienced management and scientific staff
• Headquartered in South Korea(2005) and trading on the Canadian Stock Exchange
• Planning dual listing on NASDAQ in 2019
Classification Key Content
Aug. 2005 Company founded (Paid-in capital of USD 50,000)
Jan. 2012 Established Biocurepharm-MG in Singapore, co-founded by Macauley Gehler(BPK holds 50% stake)
Aug. 2012 Attracted USD 500,000 foreign investment by Macauley Gehler Singapore
Jul. 2016 Contracted IPO in Canada stock market with Columbia Capital Inc.
Oct. 2016 Established Biopharma-Swiss in Switzerland, co-founded by Sibitec (the largest shareholder 34%)
Oct. 2016 Development of Hair Growth product containing stem cells, three recombinant human growth factors
Oct. 2016 Contracted joint venture for FMD Vaccine production with Pharos Vaccine, Korea
Sep. 2017 Launched RCHG (Recure Cell Hair Growpac)
Nov.2017 Listed in the Canada Stock Exchange (CSE)
Dec.2017 Announced clinical trial of CAR-T as the nation’s first
Jan.2018 Launched RCAW (Anti-Wrinkle) and RCPW (Pure Whitening)
Jun.2018 OTC listing obtained in the US
Oct.2018 Completed pre-clinical trial of CAR-T as the nation’s first in Korea
Company Milestones
▪ RCHG, RCAW, RCPW launched
➢ Development of human growth
factors as cosmetic ingredient ➢ Foot and Mouth Disease Vaccine
➢ Using recombinant protein as
opposed to cell culture
▪ CAR-T Cell therapy preclinical completed in 2018
▪ Clinical trial Scheduled for late-2019
➢ Ongoing - to commercialize the
first CAR-T cell therapy in Korea
Main Business Category
▪ Interferon-ß preclinical in progress to be
completed in 2019.
➢ Biosimilar and biopharmaceuticals
development
➢ Join Venture Project (in the field of
technology support)
➢ BiocurePharm’s therapy is based on genetic recombinant protein technology, and developed with collaborators in
various fields
The Plan
• BioCure can reach commercialization of its products by 2020
• Estimating to reach over USD 100m revenues with circa USD 80m EBITA by 2022
• We plan to release new products each year
• Expansion via M&A of smaller companies and additional IP for BioSimilars
• 8 commercial BioSimilars product portfolio by 2025
d 2018 20192018Classification Project 2018 2019 2020 2021
Biopharmaceu
ticals
CAR-T therapy
Interferon-β
Ranibizumab
PEG-Filgrastim
Classification Product 2017 2018 2019 2020
Overseas network
FMD
Clinical Launching
Clinical LaunchingPre-clinical
ClinicalPre-clinical
ClinicalPre-clinical
Approval
1 contract1 contract
1 contract 1 contract
Pre-clinical
Company Roadmap
H1 2019 USD 5m round
$3m CAR-T Clinical Trials in Korea
$1m Working capital
$1m Completion of pre-clinical trial for Interferon Beta in Korea
H2 2019 USD 10m round
$7m Completion of Clinical Trials for CAR-T in Korea / Start
Clinical Trials for CAR-T in Germany
$1m NASDAQ listing preparation
$1m Start Clinical Trail for Interferon Beta in Brazil / Turkey
$1m Working capital
Latest Capital Raise
C$1,103,749 by issuing 96,404 new shares of Korean Subsidiary
on Feb. 28, 2019 through a private placement to Bio- Healthcare
Association, a leading group in Biotech industry in Korea
Financing Roadmap
BiocurePharm Corp. (Korean Subsidiary)
• Outstanding Shares 3,688,236
• CURE ownership 3,591,832 (97.4%)
• Outstanding Options / Warrants Nil
BiocureTechnology
Cap Table
Biocure Technology Inc. (CSE: CURE)
• Outstanding Shares 96,793,301
• Outstanding Options 4,500,000
• Outstanding warrants 1,895,340
• Insiders’ holdings 30%
(Unit : USD)
Classification Project Period Funding Party Amount
AntibioticsThe shortest commercialization of Anti-TNF-Alpha
McAb(Infliximab), an Antibiotics. 2007.5~2008.4
Ministry of Knowledge
Economy700,000
Biopharmaceuticals
(Anti-Cancer)
Research for optimal indication and non clinical trial to
commercialize new solid cancer treatment,
ATIMPISTATIN(HAS-TIMP-2)
2007.7~2010.7Ministry of Knowledge
Economy2,500,000
Biopharmaceuticals
(Anti-Cancer)
Verification for increased efficacy of anti-cancer that inhibits
angiogenesis by PET/CT/SPECT for animals2007.7~2009.6
Small and Medium
Business
Administration
1,000,000
Diagnostics(Cancer)Diagnostic commercialization and Development for monitoring
by specific antigen for colorectal cancer2007.7~2010.6
Ministry of Health and
Welfare770,000
Stem cell treatmentNon clinical trial of developing treatment for hair loss using
adipose derived stem cell media.2013.3~2014.9
Ministry of Health and
Welfare106,000
Biosimilar
Production of API for non clinical trial sample preparation of
multiple sclerosis treatment. Development of formulation for
interferon beta1b, MS treatment
2018.8~2018.9
2018.10~2018.12Daejeon Tech Park 180,000
Others
(Recombinant protein
for material)
Development of manufacturing process for Vesicular
Endothelial Growth Factor in Saccharomyces cerevisiae2018.12~2019.02 Daejeon Tech Park 100,000
Total 5,816.000
Government Funded Research
▪ BiocurePharm’s CAR-T Cell therapy is 2nd generation using CD-19
▪ BiocurePharm established standard protocols for the conditions of CAR-T Cell therapy, re-injection,
management of side-effects, and combined therapy with other programs
▪ BiocurePharm will have the 1st CAR-T therapy clinical trial in Korea
▪ Pre-clinical trial completed in 2018
▪ Clinical trial is scheduled for late-2019
CAR-T cell immunotherapy
- Chimeric Antigen Receptor modified T cell therapy
- The most competitive and advanced treatment for
Acute lymphoblastic leukemia (ALL)
Fig. copyright@2015 Norvatis
CAR-T Cell therapy in BiocurePharm
Comparision of developing for anti-cancer drug
developement1st (chemical-) 2nd (Specific-) 3rd(Immuno-)
▪ Anti cancer drug with cellular toxins to
induce cell death
▪ Attacking cancer cell with specific
reaction
▪ Reactivation for immunity
▪ Improvement for immune system
▪ Very high toxicity (secondary cancers)
▪ Not effective in all patients
▪ Also normal cell are killed
▪ Lower side effect than 1st generation
▪ Variable efficiency
▪ Resistance will develop
▪ High efficiency
▪ Complete recovery
▪ Natural treatment by memorial immune
system
- Emily Whitehead
1ST patient to participate clinical trial for CAR-T
Cell immunotherapy
She is 18 years old and recovered completely.
She is living cancer free more than 5 years
after treatment
- Chimeric Antigen Receptor modified T cell therapy
Immuno-cell therapy : CAR-T Cell therapy
▪ CAR-T Cell for Acute lymphoblastic leukemia (ALL)
▪ Competitive treatment individually customized for the blood cancer
▪ Novartis has shown 83% complete response for the patients who are terminally ill
[Mechanism]
▪ The treatment: Extracts T-Cells from the patient’s blood and modify the cells with a specific virus
▪ Then grows the modified cells and inject back in the patient. Now cells kill the cancer
Immuno-cell therapy : CAR-T Cell therapy
Coherent Market Insights, CAR-T Cell therapy market (2017.2)
Global Market size and prediction of CAR-T cell therapy (2017-2028, million dollars)
Market size (million$)
Growth rate year on year (%)
▪ The 1st CAR-T Cell therapy Kymriah was launched in late 2017(USA) and 2018(EU) by Novartis
▪ The therapy is expected to benefit many leukemia patients – old and young
▪ According to a 2015 NIH report there are more than 340,000 patients in the U.S. suffering from leukemia
▪ The global CAR-T cell therapy market is growing at an explosive rate
▪ Annual growth rate is expected to average around 53.9% (2017-2028)
▪ The market value for CAR-T cell therapies is anticipated to be significant
- Chimeric Antigen Receptor modified T cell therapy
Immuno-cell therapy : CAR-T Cell therapy
- Chimeric Antigen Receptor modified T cell therapy
Documents to apply for clinical trial
✓ Nonclinical toxicity and distribution completed
✓ Establishment of the specification and assay completed
✓ Manufacturing in GMP is in process
✓ CMC(Chemistry, Manufacturing and Control) completed
Choose the clinical center
Submit plan for trial
Application for IND Status
CAR-T Cell therapy in BiocurePharm
CAR-T Cell Immunotherapy
Coherent Market Insights, CAR-T Cell therapy market (2017.2)
CAR-T Cell therapeutics by target antigen market statue and forecast (2017-2028, million dollars)
▪ Comparing the CAR-T Cell therapeutics market by target antigen, the market for CD19 antigen steadily maintains the
largest share of the market
▪ Studies on CAR-T Cell therapeutics using CD19 as a target antigen are actively under way.
Process of manufacturing for BCP019_ Lentiviral vectors- Chimeric Antigen Receptor modified T cell therapy
(Replication Competent Lentivirus Assay)
- Chimeric Antigen Receptor modified T cell therapy
▪ PBMC (Peripheral Blood Mononuclear Cell)
Process of manufacturing for the Drug Product, BCP019
Re-injection into body to attack and kill a cancerous
cells after making CAR-T cell using T cell extracted
from patient’s blood
Development and Efficacy Test - Chimeric Antigen Receptor modified T cell therapy
➢ Confirmation of BCP019 CAR-T
therapy for leukemia on animal
model test
Construction of Letiviral vector system Genetic transduction into T cell Efficacy test (Preclinical)
BCP019_ Safety Test- Chimeric Antigen Receptor modified T cell therapy
Efficacy DistributionSingle to
toxicity
Repeat to
toxicity
Genetic
toxicity
Carcinogen
eticity
Reproducti
on toxicityOthers
O O O X X △ X △(Local)
Toxicity test
Single to toxicity
- Single administration
- Test Model: Nude mice
(6 males and females per a test)
- How to inject: intravenous
- Dosing: Low, middle, High
→ maximum dose considering safety
- Period: 28 days
Results :
There is not any specific toxicity to test, when the BCP401 inj
ects individually single administration into immunodeficienicy
animal Balb/c nu/nu mouse. The NOAEL is maximum dose,
5x10^7 cells/head.
Distribution
- Single administration
- - Test Model: Nude mice
(5 males and females per a test)
- How to inject: intravenous
- Dosing : maximum dose considering safety
- Test organs: Inguinal LNs, Lung, Heart, Kidney, BM, Liver, Gut,
Skin, Blood, Spleen, Gonads, Brain
- Detection for BD: qPCR by validated protocol
Results :
The test results indicate that the foreign substance, BCP40
1 will be completely eliminated on 7th and 28th days after ad
ministrating it to the immunodeficiency animal Balb/c nu/nu
mouse. That means there will be little toxic effects that rem
ain to affect other organs
Currently stage of BCP019: Production of sample for Clinical trial
- Chimeric Antigen Receptor modified T cell therapy
BCP019 IND filing
➢ Preclinical efficacy / toxicity test completed
➢ SOP and Specification for manufacturing on GMP facility
➢ CMC (Chemistry, Manufacturing and Control)
Development of Clinical
protocol
→ IND apply
Current stage
- Chimeric Antigen Receptor modified T cell therapy
➢Clinical hospital or institute
➢ Korea : Seoul National University Hospital, Asan Medical Center
➢Germany : Berlin Charite Univ. (Brandenburg Center for Regenerative
Therapies) Initial agreement
➢ Expected date for Korean IND submission
➢ AUG 2019
➢ Expected date for clinical trial
➢ Korea : 3Q 2019 (Targeted by Jul. 31, 2019)
➢Germany : 4Q 2019 (Documentation of IND in Korea will be submitted to
EMEA)
Plan for Clinical trial of BCP019
- Chimeric Antigen Receptor modified T cell therapy
Plan for production, GMP facility and advance for global market
Area Plan Progress
KoreaIt will be established in a Science business belt in Daejeon city on a site
already owned by Biocure Pharm
Design in 2019,
Completed in 2021
Germany Using the existing GMP facility in the Charite institute, Berlin In progress with local
partner in Germany
Canada Using the GMP facility for producing cell therapy in Toronto, CCVP (The
Centre For Cell and Vector Production) and BCCA, Victoria, BC
It is scheduled to discuss in
2019
Sweden Initiating talks with Karolinska Hospital and Sahlgrenska
Asia Negotiating with Wellness Hospital to establish a facility in Malaysia first In Negotiation
Others Italy, Austria, Swiss, Poland, Russia etc
▪ If existing facilities and production systems are available, it will be advantageous for the business to proceed.
- Chimeric Antigen Receptor modified T cell therapy
Further R&D planning on basis of the CAR-T therapy
➢ Targetable to Solid tumor
: Pancreatic cancer, Lung cancer, Ovarian cancer
① Development of new treatment for solid cancers using antibody technology of Y biologics that have various libraries
of antibody and developing techniques
② Development of treatment for solid cancers using combination injection with IL-2 and IL-7
➢ Joint research with our networks in Canada, Germany, U.S
▪ Germany : Probiogen
▪ Canada : UBC and/or UVIC (University of British Columbia or University of Victoria)
The possibility of solid cancer target treatments using CAR-T cell is seen as likely and important
No CAR-T cell treatment for solid tumor has been approved by the FDA yet
Several early clinical studies have indicated inroads to successful treatment in solid cancers
Reporter Jong Won Chang at Biospecdata on January 8, 2019
Y Biologics - Biocurepharm‘ ICI+CAR-T Combined Therapy’ Development of Anticancer Treatment for Solid Tumors
Anti PD-1 Mono Clone Antibody YBL-006 & Anti-CD-19 CAR-T Combined Therapy
Development
The purpose of this agreement is to research the effectiveness of combined treatment of Immune Checkpoint Inhibitor
PD-1 (Programmed Cell Death Protein-1)developed by YB and anti-CD19 CAR T-Cell Therapy developed by BPK.
Next Generation Anticancer Treatment for Solid Tumors.
Patent issue for CD19_CAR-T cell therapy
◼ Comparison of BCP019 and Kymriah(CTL019)
BCP019 Kymriah
Company BiocurePharm Novartis
Molecular target ◼ CD191) : Same
Structure◼ 2nd generation CAR
anti-CD19 binding domain / intermembrane domain / co-stimulating domain
Stimulating site
CD3ζ(zeta)Amino acid Sequence of St. Jude Some amino acid altered
Anti-CD19 binding domain Mouse antibody(FMC63 scFv)2) Humanized antibody3)
1) CD19 is a cell surface component of the B cell receptor complex involved in B cell activation
2) The sequence of FMC63 scFv is already opened in 1997. : Construction and characterization of a functional CD19
specific single chain Fv fragment for immunotherapy of B lineage leukemia and lymphoma. (Nicholson et al. Mol. Immun.
34(16-17) : 1157-1165(1997))
3) Novartis patent is “WO2014153270A1, Treatment of cancer using humanized ant-cd19 chimeric antigen receptor”
4) The original patent of St. Jude will be expire 2023, and that is only entitled to the U.S.
M&A and contracts of CAR-T cell related companies
Company Product Relation information Comment
Celgene
JCAR015
JCAR017
JCAR019
Juno therapeutics was acquired for $9 billion in Jan.
2018
Juno therapeutics was not approved because
patient died in the clinical trial for JCAR015 of
Juno therapeutics
NovartisKymriah
($475,000)
Pennsylvania university had co-studied with Novartis
and Kymriah was launched in 2017First approved CAR-T
GileadYestcarta
($373,000)
Kite Pharm was acquired for $12 billion in Oct.
2017
Cell design labs was acquired for $ 0.5 billion in 2018
Cell design lab has on/off switchable technique
Kite Pharm KTE-C19
Contract of development and Sales right with
Daichisankyo in Japan
Established Joint Venture with Pusing pharm in China
Contract of partnership of Amgen, Genenetech, GE,
NIH, Biotech etc.
Kite pharma established the facility that can
supply up to 5,000 patients per year around LA
airport
Competitive Advantage
• BioCure is well positioned to gain leadership with advanced CAR-T solutions
• BioCure is an early Biosimilars entrant with strong knowhow and products already in development
• Biosimilars market development is in its early stages
• Competition is limited in comparison to Generic drugs
• Biosimilars have high barriers to entry as they require unique knowhow – e.g. – there are only three known competitors for BioCure MS product (Interferon Beta)
BiocureTechnology
The incidence of Lymphoid Leukemia in Korea
Source –Current state of hematologic malignancy and hematodyscrasia and
an analysis of blood transfusion amounts
- Age-specific lymphoid leukemia patients
-Current state of age-specific lymphoid leukemia with newly
diagnosed cases
▪ Total number of Lymphoid Leukemia patients has been increased by 5.7 percent annually and in 2015, newly
diagnosed cases were 1,008.
▪ It is a rare disease in incidence criteria but has a high incidence rate to infants.
▪ In 2016, cumulative number of patients was 5,745 but patients under 19 were 2,654 which accounted for 46
percent.
▪ That was 0.005 percent of Korea’s population.
The incidence of Lymphoid Leukemia per country
Source – Cancer causes control
- Age-specific ALL incidence(2003-2007) : people/for every 100,000 people
▪ According to WHO(2003-2007), age-specific ALL incidence varies by
region and Western Europe , America, and Oceania are having a
higher incidence rate than Eastern Europe and Asia – both incidence
rate and the number of patients have been increasing.
▪ WHO(2003-2007): age-specific ALL incidence is related with
diagnostic technique and socio-economic backgrounds.
▪ Lymphoid leukemia occurs more frequently in people under the age
of 19. - ALL Onset prediction(2015) : Number of patients(people)
CAR-T Cell Immunotherapy - Marketing Plan
▪ (Korea) Total number of Acute Leukemia patients(ALL) is about 5,000 (including 2,600 of
Infants) and approximately 1,000 new cases are reported every year, with 5.7 percent
annual growth rate.
▪ (International) A number of acute Leukemia patients varies by country but roughly 50 –
3,000 new cases are reported every year. The number of patients has been increasing
and the market size is also expected to increase.
▪ Clinical trials are conducted in Korea, Europe, Canada, Asia, South America, and North
America as well as the product launch. The below tale shows our target number of
patients in the market.
Area Launching Year Number of Patients
Korea 2020-2021 100
Europe, Canada 2021-2022 300-600
Asia, South America 2021-2022 300-400
USA 2024- 500
• “…BioSimilars will provide access to important therapies for patients who need them…”FDA Commissioner Margaret A. Hamburg M.D.
BiocureTechnology
Biosimilar and Biopharmaceuticals by
Biocurepharm
➢Multiple Sclerosis Treatment : Interferon β
➢Combine therapy for Anti cancer and blood disease : PEG-GCSF
➢Macular Degeneration Treatment : Ranibizumab
Current Market Conditions
▪ Multiple Sclerosis Market size in 2017 was approximately USD
21.5 billion
▪ One of the blockbuster bio-similar candidates
▪ Main players are 3 companies in the world
▪ There are many patients in the Middle East, North Africa,
Eastern Europe, and Brazil that do not have the same access
as patients in the major countries
▪ Completed preparation for mass production
▪ Progressing to preclinical trial
Status of Current Development
▪ Middle Eastern, North African and Brazilian markets first
▪ Main production will be with the joint venture companies in
Turkey and Iran
▪ Current market average sales price is about USD 350/vial
▪ Manufacturing cost is extremely low compared to selling price
Market entry strategy
▪ It will take 24 months to complete the pre-clinical and
clinical trial processes
Entry barrier
Biopharmaceuticals : Interferon-β
Current Market Conditions
▪ Filgrastim is an anti-cancer treatment that plays an important
role for the recovery of cancer patients’ immune system
▪ Amgen created a market of more than USD 6 billion by selling
the first general drug called Neupogen (Filgrastim)
▪ Sales of second generation Neublasta (PEG-GCSF) are
increasing in the total market for GCSF (ONE injection vs. daily)
▪ Several companies produce the first generation Filgrastim
▪ Plan to produce the second generation product the patent for
which expired in 2016 by bio-similar
▪ Already secured production technology of the first generation
of Filgrastim
Status of Current Development
▪ BiocurePharm will launch this product in Middle East, Eastern
Europe, Turkey, Indonesia, Thailand and Malaysia through
overseas partners as the first stage
▪ The product will be price-competitive with highest quality
Market entry strategy
▪ It will take 28 months to complete pre-clinical and clinical
trial processes
Entry Barrier
Biopharmaceuticals : PEG-Filgrastim(G-CSF)
Current Market Conditions
▪ Novartis entered the market with “Lucentis”
▪ Annual market size is more than 9 billion as of 2017
▪ Potential demand is increasing rapidly and currently many
pharmaceutical companies want self production
▪ Production cost is forecasted to be extremely low compared to
selling price
▪ Novartis Patent expired (2017)
Status of Current Development
▪ We can gain major maker share through price competiveness
and best quality in emerging markets
▪ In the Korean market, the product will be launched through an
alliance with a domestic pharmaceutical company
▪ For overseas markets, exports target where the company’s
partners are: Eastern Europe, Brazil, Middle East, Southeast
Asia and Turkey
Market entry strategy
▪ Will begin pre-clinical trial as soon as possible
Entry barrier
▪ It can be produced by recombinant E.coli
▪ Production is possible immediately away without additional
investment in facilities
Fig. Proportion of Elderly Population by Country (Aged 65 years and over)
Source: Statistics Bureau, MIC, Ministry of Health, Labor and Welfare; United
Nations.
Biopharmaceuticals : Ranibizumab
• Sang Mok Lee, CEO & President, Director
Dr. Lee has been a President and CEO since the inception in 2005. Dr. Lee holds a PhD in microbiology from Busan National
University in Korea and is currently an adjunct professor in microbiology at Chungnam National University. Dr. Lee is a
committee member for the hi-tech medical complex city in Daejon, Korea and a committee member of KOFST (the Korean
Federation of Science and Technology Societies).
• Konstantin Lichtenwald, CFO, Director
Mr. Lichtenwald has over ten years of finance and accounting experience, including corporate compliance, accounting and
financial management and IPO, RTO services. Mr. Lichtenwald offers extensive knowledge and know-how for companies in
two key financial jurisdictions, North America and German speaking parts of Europe. His accounting, financial skills offer a
multi-faceted hands on approach to strategic management and problem solving. Mr. Lichtenwald earned his bachelor of
business administration degree from Pforzheim University, Germany, and holds the professional designation of Chartered
Professional Accountant (CPA, CGA) and Chartered Certified Accountant (ACCA), where he is a member of Chartered
Professional Accountants of B.C. and Canada as well as a member of the Association of Chartered Certified Accountants of
United Kingdom.
• Collin (Sang Goo) Kim, Director
Mr. Kim holds a bachelor degree of business administration from Korea University, Seoul, Korea. Mr. Kim came to Vancouver, Canada in 2006
after working for Hanwha Corp., one of Korean business conglomerates for 16 years, where he was dedicated to International trading business for
various industrial products. He has been working as a Vice President for Columbia Capital since 2008 and a director of ArcPacific Resources
Corp., a public Canadian junior exploration company, since 2015. He is imperative in the communication between Korean management and
Canadian management cross the border with his vast knowledge and work experience.
The Team
• Hans Frykman – Director
Dr. Hans Frykman is the current medical director of Neurocode Labs in Vancouver and UBC Diagnostic Services Lab. Neurocode is world
leading in the field of neurogenetics accepting difficult adult and pediatric neurology cases from Asia, North America and Europe. It is Canada’s
first and only clinical whole exome sequencing laboratory. Also, Neurocode has a best in class software product linking genotype to phenotype in
the area of neurogenetics. UBC Diagnostic Services Lab is Canada’s leading clinical Neuroimmunology laboratory servicing all provinces with this
highly complex testing. Under Dr. Frykman’s guidance, the UBC Diagnostic Services lab has expanded fourfold. Dr. Frykman has a medical
degree from Karolinska Institute in Stockholm, a PhD in Biocatalysis at Royal Institute of Technology, and post graduate medical training from
Karolinska University Hospital Solna Campus, Mayo Clinic, University of Minnesota, Memorial Sloan Kettering and University of British Columbia
in the areas of internal medicine, oncology, clinical pathology, molecular genetics and medical biochemistry. Dr. Frykman held reaearch positions
with the US Government, Astra Zeneca, Akzo Nobel and Novo Nordisk. Early in his career he was part of the discovery teams around Victoza and
Losec(Prilosec). He is licensed to practice medicine in Sweden and British Columbia.
• Danny Joh – Director
After completing a PhD in Biochemistry at Texas A&M university and an MBA at Rice University, Danny Joh moved to the San Francisco area to
build a career in the biopharma industry. For twenty years, he has expanded his biopharma product development and cross-functional program
management experiences while working for major biopharma companies, including Chiron, Genentech, Biomarin, Sangamo and other biotech
companies in the San Francisco area. His experience spans from early to late stage product development in various platforms, including
biologics, small molecules, and gene therapy across many therapeutic areas, including cancer and rare genetic disorders. He joins the Board of
Directors of BioCure Technologies in March, 2019.
• The Company also has a very strong Advisory Board comprised of Medical Professionals that have key industry contacts and
alliances. For their full Bio’s and Summary of expertise please refer to our website.
The Team